Bio-Rad launches Vericheck ddPCR Kits for QX700 System to advance biopharma QC and cell and gene therapy workflows
New Vericheck ddPCR™ kits bring validated, ready-to-use quality control assays to the QX700™ Digital PCR platform
10 Jul 2026Product news
Bio-Rad Laboratories, Inc. has launched its QX700™ System-compatible Vericheck ddPCR™ Kit portfolio to support critical quality control (QC) workflows in advanced cell and gene therapy development and other biopharma applications.
The new Vericheck ddPCR Kits are designed for highly specific and highly sensitive DNA detection and quantification, enabling biopharmaceutical developers and manufacturers to improve product safety, quality, and development timelines.
New Vericheck ddPCR Kits for key biopharma QC applications
The Vericheck ddPCR Kit portfolio extends Bio-Rad’s existing droplet digital PCR (ddPCR) platform with ready-to-use, application-focused, validated kits tailored to high-priority QC workflows in biopharma, including cell and gene therapy.
The portfolio includes:
- Vericheck ddPCR Mycoplasma Detection Kit
- Vericheck ddPCR Empty-Full Capsid Kit
- Vericheck ddPCR Replication Competent Lentivirus Kit
- Vericheck ddPCR CHO Residual DNA Quantification Kit
- Vericheck ddPCR E. coli Residual DNA Quantification Kit
These kits are intended to support critical QC testing needs such as contamination monitoring, vector characterization, replication-competent virus testing, and residual host cell DNA quantification.
QX700 System performance and workflow scalability
Bio-Rad’s QX700 platform provides seven-color multiplexing and the capacity to process up to 384 reactions in around two and a half hours. The system is designed for minimal input volume, continuous loading capability, and easy-to-use software to streamline data interpretation.
By combining the performance of the QX700 Systems with the Vericheck ddPCR Kits, researchers and biopharma manufacturers can generate precise, reproducible, and faster results to support product development, product safety, and product quality.
Supporting advanced therapeutic development and manufacturing
In advanced therapeutic development and manufacturing, QC testing is essential to ensure the safety and effectiveness of cell and gene therapy products and other biologics. The Vericheck ddPCR Kits provide validated workflows that help improve confidence in:
- Vector characterization, including empty-full capsid analysis
- Contamination detection, including mycoplasma
- Replication-competent virus testing, such as replication competent lentivirus
- Residual host cell DNA quantification from CHO and E. coli production systems
By offering a complete and accessible solution for these high-priority QC testing needs, the Vericheck ddPCR Kits are designed to help biopharma developers meet regulatory expectations and maintain consistent product quality.
“The expansion of our range of Vericheck ddPCR Kits offers validated workflows with unmatched precision and sensitivity, combined with the power of the QX700 platform, enabling scalable, streamlined workflows and faster time to actionable results,” said Stephen Kulisch, Vice President of Marketing, Digital Biology Group, Bio-Rad.
“By expanding the power of our QX700 platform through the development of this new portfolio of Vericheck Kits, Bio-Rad is continuing its commitment to support development of safer and more efficient advanced therapeutic development and manufacturing.”
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
What are Bio-Rad’s Vericheck ddPCR Kits and how do they support cell and gene therapy QC?
Bio-Rad’s Vericheck ddPCR™ Kit portfolio is a set of ready-to-use, validated droplet digital PCR kits compatible with the QX700™ System. They enable highly specific and sensitive DNA detection and quantification to support critical QC workflows in advanced cell and gene therapy development, helping biopharma developers improve product safety, product quality, and development timelines.
Which QC applications are addressed by the Vericheck ddPCR Kit portfolio for biopharma developers?
The Vericheck ddPCR Kit portfolio supports key biopharma QC applications, including contamination monitoring, vector characterization, replication-competent virus testing, and residual host cell DNA quantification.
Specific kits include Mycoplasma Detection, Empty-Full Capsid, Replication Competent Lentivirus, CHO Residual DNA Quantification, and E. coli Residual DNA Quantification, tailored to high-priority workflows in cell and gene therapy and other biologics manufacturing.
How does the Bio-Rad QX700 System enhance Vericheck ddPCR Kit performance for biopharma QC?
The Bio-Rad QX700 System offers seven-color multiplexing and can process up to 384 reactions in about two and a half hours with minimal input volume and continuous loading. Combined with Vericheck ddPCR Kits, it delivers precise, reproducible, and faster results, streamlines data interpretation with easy-to-use software, and supports scalable QC workflows for advanced therapeutic development and manufacturing.